Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen

HIV Clinical Trials

Volumn 8, Issue 5, 2007, Pages 259-268

  Loutfy, Mona R ^a   Ackad, Nabil ^b   Antoniou, Tony ^c   Baril, Jean Guy ^d   Conway, Brian ^e   De Wet, Joss ^e   Trottier, Benoit ^f   Kovacs, Colin M ^a   Thompson, William ^g   Martel, Alain Y ^h,i   Trottier, Sylvie ⁱ   Rouleau, Danielle ^j   Shafran, Stephen D ^k   Rachlis, Anita ^a   Fraser, Christopher ^l   Smaill, Fiona ^m   Walmsley, Sharon L ^a   Tseng, Alice L ⁿ   Sampalis, John S ^h,o,p  

^a UNIVERSITY OF TORONTO   (Canada)

^b ABBOTT LABORATORIES   (United States)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d Clinique Medicale du Quartier Latin   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f Clinique Medicale l'Actuel   (Canada)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

^h Clinique Médicale des Campus ^*  (Canada)

ⁱ LAVAL UNIVERSITY   (Canada)

^j UNIVERSITÉ DE MONTRÉAL   (Canada)

^k UNIVERSITY OF ALBERTA   (Canada)

^l The Cool Aid Community Health Centre   (Canada)

^m MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

ⁿ UNIVERSITY OF TORONTO   (Canada)

^o INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^p MCGILL UNIVERSITY   (Canada)

more..

Author keywords

Antiretroviral (ARV) therapy; Clinical trial; HIV; Lopinavir ritonavir (LPV r); Randomized

Indexed keywords

LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; TENOFOVIR;

ABDOMINAL DISTENSION; ABSCESS; ADULT; AMNESIA; ANTIVIRAL ACTIVITY; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIVERTICULITIS; DRUG DOSE REDUCTION; FATIGUE; FEMALE; FLATULENCE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NAUSEA; PANCREATITIS; PNEUMONIA; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RECTUM DISEASE; SEIZURE; SUICIDAL IDEATION; URETHRA STONE; VIRUS INFECTION; VIRUS LOAD; VOMITING;

ADENINE; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PROSPECTIVE STUDIES; PYRIMIDINONES; RITONAVIR; VIRAL LOAD;

EID: 36049018986     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0805-259     Document Type: Article

References (20)

1. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997;349:1294.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
3. Selik RM, Karon JM, Ward JW. Effect of the human immunodeficiency virus epidemic on mortality from opportunistic infections in the United States in 1993. J Infect Dis. 1997;176:632-636.
4. Negredo E, Bonjoch A, Clotet B. Benefits and concerns of simplification strategies in HIV-infected patients. J Antimicrob Chemother. 2006;58:235-242.
5. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2001;45:2733-2739.
6. Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet. 1999;36:41-66.
7. Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother. 1998;42:612-617.
8. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS. 2002;16:1257-1263.
9. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-2046.
10. Benson CA, Deeks SG, Brun SC, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis. 2002;185:599-607.
11. Eron JJ, Feinberg J, Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis. 2004;189:265-272.
12. Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. In: 52nd World Medical Association General Assembly; 2000; Edinburgh, Scotland.
13. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 2000;12:255-266.
14. Justice AC, Holmes W, Gifford AL, et al. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol. 2001;54(suppl 1):S77-S90.
15. la Porte CJ, Schippers EF, van der Ende ME, et al. Pharmacokinetics of once-daily lopinavir/ritonavir and the influence of dose modifications. AIDS. 2005;19:1105-1107.
16. Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2003;47:350-359.
17. van Heeswijk RP, Bourbeau M, Seguin I, et al. Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients. Br J Clin Pharmacol. 2005;59:398-404.
18. Johnson MA, Gathe JC Jr, Podzamczer D, et al. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr. 2006;43:153-160.
19. Gatti G, Di BA, Casazza R, et al. The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS. 1999;13:2083-2089.
20. Breilh D, Rouzes A, Djabarouti S, et al. Pharmacokinetic drug interaction of lopinavir/rotinavir in combination with tenofovir in experienced HIV+ patients. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004; Washington, DC. Abstract A-445.